《现代医学与健康研究》编辑部官网!【中国医师协会系列期刊】
布林佐胺联合噻吗洛尔在新生血管性青光眼 术后的应用效果
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R775.1

基金项目:


Postoperative application effect of Brinzolamide combined with Timolol in the treatment of patients with neovascular glaucoma
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的 分析布林佐胺联合噻吗洛尔治疗新生血管性青光眼术后患者,对其视网膜中央动脉血流收缩期峰值速度(PSV)、舒张 末期速度(EDV)、阻力系数(RI)、白细胞介素 -6(IL-6)、色素上皮衍生因子(PEDF)、血管内皮生长因子(VEGF)水平的影响, 以期为临床诊治该疾病提供参考依据。方法 选取盐城顾泽潮聚眼科医院 2020 年 8 月至 2021 年 5 月期间,接受全视网膜光凝术 + 小梁 切除术治疗的新生血管性青光眼患者 86 例,以随机数字表法将其分为对照组(43 例)与观察组(43 例)。对照组患者术后采用噻吗洛尔 滴眼治疗,观察组患者在噻吗洛尔滴眼的基础上采用布林佐胺滴眼治疗,两组患者均治疗 1 周。比较治疗前后两组患者眼压、视野平均光 敏度、视野平均缺损度、PSV、EDV、RI、IL-6、PEDF、VEGF 水平,以及治疗期间眼部疼痛、头痛、眼内干涩发生情况。结果 治疗后 两组患者眼压、视野平均缺损、RI、IL-6、VEGF 水平均显著低于治疗前,且观察组显著低于对照组,而视野平均光敏度、PSV、EDV、 PEDF 水平均显著高于治疗前,且观察组显著高于对照组(均P<0.05);治疗期间两组患者眼部疼痛、头痛、眼内干涩等不良反应总发生 率比较,差异无统计学意义(P>0.05)。结论 布林佐胺联合噻吗洛尔治疗可降低新生血管性青光眼术后患者眼内压,改善视网膜中央血 流动力学与视网膜功能,降低患者机体炎症因子水平,且安全性良好。

    Abstract:

    Objective? To analyze the influence of Brinzolamide combined with Timolol on central retinal artery peak systolic velocity (PSV), end diastolic velocity (EDV), resistance index (RI), interleukin-6 (IL-6), pigment epithelial derived factor (PEDF), vascular endothelial growth factor (VEGF) in the treatment of postoperative patients with neovascular glaucoma, in order to provide an effective reference for clinical diagnosis and treatment. Methods A total of 86 patients with neovascular glaucoma who received panretinal photocoagulation +trabeculectomy from August 2020 to May 2021 in Yancheng Guze Chaoju Eye Hospital were selected and divided into control group (43 cases) and observation group (43 cases) by random number table method. Patients in the control group were treated with Timolol eye drops after operation, patients in the observation group were treated with Brinzolamide eye drops on the basis of Timolol eye drops, both groups were treated for 1 week. Intraocular pressure, average visual field sensitivity, average visual field defect, PSV, EDV, RI, IL-6, PEDF, VEGF levels before and after treatment, and the occurrence of eye pain, headache and dryness during treatment were compared between the two groups. Results After treatment, intraocular pressure, average visual field defect, RI, IL-6 and VEGF levels in the two groups were significantly lower than those before treatment, and the observation group was significantly lower than the control group, the average visual field sensitivity, PSV, EDV, PEDF levels were significantly higher than those before treatment, and the observation group was significantly higher than the control group (all P<0.05); during the treatment period, there was no significant difference in the total incidence of adverse reactions such as eye pain, headache and intraocular dryness between the two groups (P>0.05). Conclusion? Brinzolamide combined with Timolol can reduce intraocular pressure in postoperative patients with neovascular glaucoma, improve central retinal hemodynamics and retinal function, reduce the level of inflammatory factors in patients, and with good security.

    参考文献
    相似文献
    引证文献
引用本文
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2022-08-24
  • 出版日期:
文章二维码

地址:北京朝阳区北沙滩1号16信箱

邮编:100083

电话:010-64882183 64883630

E-mail:xdyx2020@vip.163.com


温馨提示:建议您使用Chrome80、火狐74+、IE11浏览器 ,当您的浏览器版本过低,可能会影响部分功能正常使用。

现代医学与健康研究 ® 2024 版权所有

技术支持:北京勤云科技发展有限公司